TLR7 and neoplasm: Immunologically “cold” tumors, such as pancreatic and prostate [58], may benefit from TransCon TLR7/8 Agonist therapy via innate immune cell activation, promotion of tumor antigen presentation, and recruitment of tumor-specific cytolytic T cells to the TME.